Sandra Andorf1, Natasha Purington2, Whitney M Block1, Andrew J Long1, Dana Tupa1, Erica Brittain3, Amanda Rudman Spergel3, Manisha Desai2, Stephen J Galli4, Kari C Nadeau1, R Sharon Chinthrajah5. 1. Sean N Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, CA, USA. 2. Sean N Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, CA, USA; Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA, USA. 3. National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA. 4. Sean N Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, CA, USA; Departments of Pathology and of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA. 5. Sean N Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: schinths@stanford.edu.
Abstract
BACKGROUND: Despite progress in single food oral immunotherapy, there is little evidence concerning the safety and efficacy of treating individuals with multiple food (multifood) allergies. We did a pilot study testing whether anti-IgE (omalizumab) combined with multifood oral immunotherapybenefited multifood allergic patients. METHODS: We did a blinded, phase 2 clinical trial at Stanford University. We enrolled participants, aged 4-15 years, with multifood allergies validated by double-blind, placebo-controlled food challenges to their offending foods. Inclusion criteria included a positive skin prick test of 6 mm or more (wheal diameter, above the negative control), a food-specific serum IgE concentration of more than 4 kU/L for each food, or both, and a positive double-blind, placebo-controlled food challenge at 500 mg or less of food protein. Exclusion criteria included eosinophilic oesophagitis and severe asthma. Participants were randomised (3:1) with a block size of four, to receive multifood oral immunotherapy to two to five foods, together with omalizumab (n=36) or placebo (n=12). 12 individuals who fulfilled the same inclusion and exclusion criteria were included as controls. These individuals were not randomised and received neither omalizumab nor oral immunotherapy. Omalizumab or placebo was administered subcutaneously for 16 weeks, with oral immunotherapy starting at week 8, and was stopped 20 weeks before the exit double-blind, placebo-controlled food challenge at week 36. The primary endpoint was the proportion of participants who passed double-blind, placebo-controlled food challenges to at least two of their offending foods. This completed trial is registered with ClinicalTrials.gov, number NCT02643862. FINDINGS:Between March 25, 2015, and Aug 18, 2016, 165 participants were assessed for eligibility, of whom 84 did not meet the inclusion criteria and 21 declined to participate. We enrolled and randomised 48 eligible participants and the remaining 12 patients were included as nonrandomised, untreated controls. At week 36, a significantly greater proportion of the omalizumab-treated (30 [83%] of 36) versus placebo (four [33%] of 12) participants passed double-blind, placebo-controlled food challenges to 2 g protein for two or more of their offending foods (odds ratio 10·0, 95% CI 1·8-58·3, p=0·0044). All participants completed the study. There were no serious or severe (grade 3 or worse) adverse events. Participants in the omalizumab group had a significantly lower median per-participant percentage of oral immunotherapy doses associated with any adverse events (27% vs 68%; p=0·0082). The most common adverse events in both groups were gastrointestinal events. INTERPRETATION: In multifood allergic patients, omalizumab improves the efficacy of multifood oral immunotherapy and enables safe and rapid desensitisation. FUNDING: US National Institutes of Health (NIH).
RCT Entities:
BACKGROUND: Despite progress in single food oral immunotherapy, there is little evidence concerning the safety and efficacy of treating individuals with multiple food (multifood) allergies. We did a pilot study testing whether anti-IgE (omalizumab) combined with multifood oral immunotherapy benefited multifood allergicpatients. METHODS: We did a blinded, phase 2 clinical trial at Stanford University. We enrolled participants, aged 4-15 years, with multifood allergies validated by double-blind, placebo-controlled food challenges to their offending foods. Inclusion criteria included a positive skin prick test of 6 mm or more (wheal diameter, above the negative control), a food-specific serum IgE concentration of more than 4 kU/L for each food, or both, and a positive double-blind, placebo-controlled food challenge at 500 mg or less of food protein. Exclusion criteria included eosinophilic oesophagitis and severe asthma. Participants were randomised (3:1) with a block size of four, to receive multifood oral immunotherapy to two to five foods, together with omalizumab (n=36) or placebo (n=12). 12 individuals who fulfilled the same inclusion and exclusion criteria were included as controls. These individuals were not randomised and received neither omalizumab nor oral immunotherapy. Omalizumab or placebo was administered subcutaneously for 16 weeks, with oral immunotherapy starting at week 8, and was stopped 20 weeks before the exit double-blind, placebo-controlled food challenge at week 36. The primary endpoint was the proportion of participants who passed double-blind, placebo-controlled food challenges to at least two of their offending foods. This completed trial is registered with ClinicalTrials.gov, number NCT02643862. FINDINGS: Between March 25, 2015, and Aug 18, 2016, 165 participants were assessed for eligibility, of whom 84 did not meet the inclusion criteria and 21 declined to participate. We enrolled and randomised 48 eligible participants and the remaining 12 patients were included as nonrandomised, untreated controls. At week 36, a significantly greater proportion of the omalizumab-treated (30 [83%] of 36) versus placebo (four [33%] of 12) participants passed double-blind, placebo-controlled food challenges to 2 g protein for two or more of their offending foods (odds ratio 10·0, 95% CI 1·8-58·3, p=0·0044). All participants completed the study. There were no serious or severe (grade 3 or worse) adverse events. Participants in the omalizumab group had a significantly lower median per-participant percentage of oral immunotherapy doses associated with any adverse events (27% vs 68%; p=0·0082). The most common adverse events in both groups were gastrointestinal events. INTERPRETATION: In multifood allergicpatients, omalizumab improves the efficacy of multifood oral immunotherapy and enables safe and rapid desensitisation. FUNDING: US National Institutes of Health (NIH).
Authors: Tetsuo Shoda; Ting Wen; Seema S Aceves; J Pablo Abonia; Dan Atkins; Peter A Bonis; Julie M Caldwell; Kelley E Capocelli; Christina L Carpenter; Margaret H Collins; Evan S Dellon; Michael D Eby; Nirmala Gonsalves; Sandeep K Gupta; Gary W Falk; Ikuo Hirano; Paul Menard-Katcher; Jonathan T Kuhl; Jeffrey P Krischer; John Leung; Vincent A Mukkada; Jonathan M Spergel; Michael P Trimarchi; Guang-Yu Yang; Nives Zimmermann; Glenn T Furuta; Marc E Rothenberg Journal: Lancet Gastroenterol Hepatol Date: 2018-05-03
Authors: Timothy E Dribin; Hugh A Sampson; Carlos A Camargo; David C Brousseau; Jonathan M Spergel; Mark I Neuman; Marcus Shaker; Ronna L Campbell; Kenneth A Michelson; Susan A Rudders; Amal H Assa'ad; Kimberly A Risma; Mariana Castells; Lynda C Schneider; Julie Wang; Juhee Lee; Rakesh D Mistry; David Vyles; Lisa M Vaughn; Daniel J Schumacher; John K Witry; Shiv Viswanathan; Erica M Page; David Schnadower Journal: J Allergy Clin Immunol Date: 2020-08-24 Impact factor: 10.793
Authors: Sharon Chinthrajah; Shu Cao; Cherie Liu; Shu-Chen Lyu; Sayantani B Sindher; Andrew Long; Vanitha Sampath; Daniel Petroni; Marco Londei; Kari C Nadeau Journal: JCI Insight Date: 2019-11-14
Authors: Shiteng Duan; Cynthia J Koziol-White; William F Jester; Scott A Smith; Corwin M Nycholat; Matthew S Macauley; Reynold A Panettieri; James C Paulson Journal: J Clin Invest Date: 2019-02-18 Impact factor: 14.808